Jose Luis ALONSO ROMERO

Antonio CCP, Alida GG, Elena GG, Rocio GS, Jeronimo MG, Luis ARJ, Anibal ND, Francisco BV, Jesus GRA, Pablo RR, Jose GM. Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial. Ann Surg Oncol. 2022 Apr;29(4):2617-2625. doi: 10.1245/s10434-021-11087-7. Epub 2021 Nov 23. PubMed PMID: 34812982.

AÑO: 2022; IF: 3.7

34812982

de la Cruz-Merino L, Gion M, Cruz J, Alonso-Romero JL, Quiroga V, Moreno F, Andres R, Santisteban M, Ramos M, Holgado E, Cortes J, Lopez-Miranda E, Cortes A, Henao F, Palazon-Carrion N, Rodriguez LM, Ceballos I, Soto A, Puertes A, Casas M, Benito S, Chiesa M, Bezares S, Caballero R, Jimenez-Cortegana C, Sanchez-Margalet V, Rojo F. Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study. BMC Cancer. 2022 Dec 3;22(1):1258. doi: 10.1186/s12885-022-10363-3. PubMed PMID: 36463104; PubMed Central PMCID: PMC9719636.

AÑO: 2022

36463104

Castillo-Guardiola V, Rosado-Jimenez L, Sarabia-Meseguer MD, Marin-Vera M, Macias-Cerrolaza JA, Garcia-Hernandez R, Zafra-Poves M, Sanchez-Henarejos P, Moreno-Locubiche MA, Cuevas-Tortosa E, Arnaldos-Carrillo M, Ayala de la Pena F, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance. Eur J Med Genet. 2022 Apr;65(4):104468. doi: 10.1016/j.ejmg.2022.104468. Epub 2022 Mar 1. PubMed PMID: 35245693.

AÑO: 2022; IF: 1.9

35245693

Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Ciruelos EM, Munoz M, Bermejo B, Margeli M, Csoszi T, Anton A, Turner N, Casas MI, Morales S, Alba E, Calvo L, de la Haba-Rodriguez J, Ramos M, Murillo L, Santaballa A, Alonso-Romero JL, Sanchez-Rovira P, Corsaro M, Huang X, Thallinger C, Kahan Z, Gil-Gil M. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. Eur J Cancer. 2022 Jun;168:12-24. doi: 10.1016/j.ejca.2022.03.006. Epub 2022 Apr 13. PubMed PMID: 35429901.

AÑO: 2022; IF: 8.4

35429901

Garcia-Saenz JA, Martinez-Janez N, Cubedo R, Jerez Y, Lahuerta A, Gonzalez-Santiago S, Ferrer N, Ramos M, Alonso-Romero JL, Anton A, Carrasco E, Chen J, Neuwirth R, Galinsky K, Vincent S, Leonard EJ, Slamon D. Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor. Clin Cancer Res. 2022 Mar 15;28(6):1107-1116. doi: 10.1158/1078-0432.CCR-21-2652. PubMed PMID: 34980598; PubMed Central PMCID: PMC9365359.

AÑO: 2022; IF: 11.5

34980598